Information Provided By: 
Fly News Breaks for May 6, 2019
ESPR
May 6, 2019 | 08:26 EDT
Credit Suisse analyst Martin Auster raised his price target for Esperion to $90 from $79 as he believes the FDA's decision to accept the BA NDA and not hold an AdCom will be viewed favorably and likely will result in substantial upside as investors price in a higher assumed regulatory PoS. While the FDA could request an AdCom at a later date, the analyst is not aware of an example where an AdCom was requested after a sponsor was told it was not needed at acceptance. Auster reiterates an Outperform rating on the shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
